Cargando…
A pilot study of fecal bile acid and microbiota profiles in inflammatory bowel disease and primary sclerosing cholangitis
INTRODUCTION: Inflammatory bowel disease (IBD) is thought to arise from an abnormal immune response to the gut microbiota. IBD is associated with altered intestinal microbial community structure and functionality, which may contribute to inflammation and complications such as colon cancer and liver...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330977/ https://www.ncbi.nlm.nih.gov/pubmed/30666146 http://dx.doi.org/10.2147/CEG.S186097 |
_version_ | 1783387067771781120 |
---|---|
author | Vaughn, Byron P Kaiser, Thomas Staley, Christopher Hamilton, Matthew J Reich, Jon Graiziger, Carolyn Singroy, Stephanie Kabage, Amanda J Sadowsky, Michael J Khoruts, Alexander |
author_facet | Vaughn, Byron P Kaiser, Thomas Staley, Christopher Hamilton, Matthew J Reich, Jon Graiziger, Carolyn Singroy, Stephanie Kabage, Amanda J Sadowsky, Michael J Khoruts, Alexander |
author_sort | Vaughn, Byron P |
collection | PubMed |
description | INTRODUCTION: Inflammatory bowel disease (IBD) is thought to arise from an abnormal immune response to the gut microbiota. IBD is associated with altered intestinal microbial community structure and functionality, which may contribute to inflammation and complications such as colon cancer and liver disease. Primary sclerosing cholangitis (PSC) is associated with IBD and markedly increases the risk of colon cancer. We hypothesized that secondary bile acids, which are products of microbial metabolism, are increased in PSC patients. AIM: Here, we profiled the fecal bile acid composition and gut microbiota of participants with IBD and PSC, as well as healthy participants. Additionally, we tested the effects of vancomycin, a proposed treatment for PSC, on gut microbiota and fecal bile acid composition in participants with IBD and PSC. METHODS: Fecal samples were collected from patients with IBD, IBD/PSC and healthy controls and fecal bile acids and DNA for microbiota analysis were extracted. Fecal bile acids were averaged over a seven-day period. For subjects with IBD/PSC, oral vancomycin 500mg twice a day was administered and fecal samples were collected for up to eleven weeks. RESULTS: Participants with IBD and PSC had less fecal microbial diversity at baseline relative to controls. While there was some evidence of altered conversion of cholic acid to deoxycholic acid, no substantial differences were found in the fecal bile acid profiles of patients with IBD and PSC (n=7) compared to IBD alone (n=8) or healthy controls (n=8). Oral vancomycin was a potent inhibitor of secondary bile acid production in participants with IBD and PSC, particularly deoxycholic acid, although no changes in liver biochemistry patterns were noted over a two week period. CONCLUSION: In this pilot study, bile acid profiles were overall similar among patients with IBD and PSC, IBD alone, and healthy controls. Microbiota diversity was reduced in those with PSC and IBD compared to IBD alone or healthy controls. |
format | Online Article Text |
id | pubmed-6330977 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-63309772019-01-21 A pilot study of fecal bile acid and microbiota profiles in inflammatory bowel disease and primary sclerosing cholangitis Vaughn, Byron P Kaiser, Thomas Staley, Christopher Hamilton, Matthew J Reich, Jon Graiziger, Carolyn Singroy, Stephanie Kabage, Amanda J Sadowsky, Michael J Khoruts, Alexander Clin Exp Gastroenterol Original Research INTRODUCTION: Inflammatory bowel disease (IBD) is thought to arise from an abnormal immune response to the gut microbiota. IBD is associated with altered intestinal microbial community structure and functionality, which may contribute to inflammation and complications such as colon cancer and liver disease. Primary sclerosing cholangitis (PSC) is associated with IBD and markedly increases the risk of colon cancer. We hypothesized that secondary bile acids, which are products of microbial metabolism, are increased in PSC patients. AIM: Here, we profiled the fecal bile acid composition and gut microbiota of participants with IBD and PSC, as well as healthy participants. Additionally, we tested the effects of vancomycin, a proposed treatment for PSC, on gut microbiota and fecal bile acid composition in participants with IBD and PSC. METHODS: Fecal samples were collected from patients with IBD, IBD/PSC and healthy controls and fecal bile acids and DNA for microbiota analysis were extracted. Fecal bile acids were averaged over a seven-day period. For subjects with IBD/PSC, oral vancomycin 500mg twice a day was administered and fecal samples were collected for up to eleven weeks. RESULTS: Participants with IBD and PSC had less fecal microbial diversity at baseline relative to controls. While there was some evidence of altered conversion of cholic acid to deoxycholic acid, no substantial differences were found in the fecal bile acid profiles of patients with IBD and PSC (n=7) compared to IBD alone (n=8) or healthy controls (n=8). Oral vancomycin was a potent inhibitor of secondary bile acid production in participants with IBD and PSC, particularly deoxycholic acid, although no changes in liver biochemistry patterns were noted over a two week period. CONCLUSION: In this pilot study, bile acid profiles were overall similar among patients with IBD and PSC, IBD alone, and healthy controls. Microbiota diversity was reduced in those with PSC and IBD compared to IBD alone or healthy controls. Dove Medical Press 2019-01-10 /pmc/articles/PMC6330977/ /pubmed/30666146 http://dx.doi.org/10.2147/CEG.S186097 Text en © 2019 Vaughn et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Vaughn, Byron P Kaiser, Thomas Staley, Christopher Hamilton, Matthew J Reich, Jon Graiziger, Carolyn Singroy, Stephanie Kabage, Amanda J Sadowsky, Michael J Khoruts, Alexander A pilot study of fecal bile acid and microbiota profiles in inflammatory bowel disease and primary sclerosing cholangitis |
title | A pilot study of fecal bile acid and microbiota profiles in inflammatory bowel disease and primary sclerosing cholangitis |
title_full | A pilot study of fecal bile acid and microbiota profiles in inflammatory bowel disease and primary sclerosing cholangitis |
title_fullStr | A pilot study of fecal bile acid and microbiota profiles in inflammatory bowel disease and primary sclerosing cholangitis |
title_full_unstemmed | A pilot study of fecal bile acid and microbiota profiles in inflammatory bowel disease and primary sclerosing cholangitis |
title_short | A pilot study of fecal bile acid and microbiota profiles in inflammatory bowel disease and primary sclerosing cholangitis |
title_sort | pilot study of fecal bile acid and microbiota profiles in inflammatory bowel disease and primary sclerosing cholangitis |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330977/ https://www.ncbi.nlm.nih.gov/pubmed/30666146 http://dx.doi.org/10.2147/CEG.S186097 |
work_keys_str_mv | AT vaughnbyronp apilotstudyoffecalbileacidandmicrobiotaprofilesininflammatoryboweldiseaseandprimarysclerosingcholangitis AT kaiserthomas apilotstudyoffecalbileacidandmicrobiotaprofilesininflammatoryboweldiseaseandprimarysclerosingcholangitis AT staleychristopher apilotstudyoffecalbileacidandmicrobiotaprofilesininflammatoryboweldiseaseandprimarysclerosingcholangitis AT hamiltonmatthewj apilotstudyoffecalbileacidandmicrobiotaprofilesininflammatoryboweldiseaseandprimarysclerosingcholangitis AT reichjon apilotstudyoffecalbileacidandmicrobiotaprofilesininflammatoryboweldiseaseandprimarysclerosingcholangitis AT graizigercarolyn apilotstudyoffecalbileacidandmicrobiotaprofilesininflammatoryboweldiseaseandprimarysclerosingcholangitis AT singroystephanie apilotstudyoffecalbileacidandmicrobiotaprofilesininflammatoryboweldiseaseandprimarysclerosingcholangitis AT kabageamandaj apilotstudyoffecalbileacidandmicrobiotaprofilesininflammatoryboweldiseaseandprimarysclerosingcholangitis AT sadowskymichaelj apilotstudyoffecalbileacidandmicrobiotaprofilesininflammatoryboweldiseaseandprimarysclerosingcholangitis AT khorutsalexander apilotstudyoffecalbileacidandmicrobiotaprofilesininflammatoryboweldiseaseandprimarysclerosingcholangitis AT vaughnbyronp pilotstudyoffecalbileacidandmicrobiotaprofilesininflammatoryboweldiseaseandprimarysclerosingcholangitis AT kaiserthomas pilotstudyoffecalbileacidandmicrobiotaprofilesininflammatoryboweldiseaseandprimarysclerosingcholangitis AT staleychristopher pilotstudyoffecalbileacidandmicrobiotaprofilesininflammatoryboweldiseaseandprimarysclerosingcholangitis AT hamiltonmatthewj pilotstudyoffecalbileacidandmicrobiotaprofilesininflammatoryboweldiseaseandprimarysclerosingcholangitis AT reichjon pilotstudyoffecalbileacidandmicrobiotaprofilesininflammatoryboweldiseaseandprimarysclerosingcholangitis AT graizigercarolyn pilotstudyoffecalbileacidandmicrobiotaprofilesininflammatoryboweldiseaseandprimarysclerosingcholangitis AT singroystephanie pilotstudyoffecalbileacidandmicrobiotaprofilesininflammatoryboweldiseaseandprimarysclerosingcholangitis AT kabageamandaj pilotstudyoffecalbileacidandmicrobiotaprofilesininflammatoryboweldiseaseandprimarysclerosingcholangitis AT sadowskymichaelj pilotstudyoffecalbileacidandmicrobiotaprofilesininflammatoryboweldiseaseandprimarysclerosingcholangitis AT khorutsalexander pilotstudyoffecalbileacidandmicrobiotaprofilesininflammatoryboweldiseaseandprimarysclerosingcholangitis |